“Consistent improvements in Global evaluation of treatment effectiveness (GETE), lung function, and patient-reported outcomes (PROs), and reductions in asthma exacerbations, oral corticosteroid (OCS) use, and healthcare resource utilization (HCRU) with add-on omalizumab in real-life confirm and complement the efficacy data of randomized control trials,” wrote the authors of a meta-analysis of observational studies in patients with severe allergic asthma treated with omalizumab for at least 16 weeks. Combined results from 86 publications showed that GETE was good/excellent in 77% of patients at 16 weeks and in 82% at 12 months. Mean improvements in FEV1 at 16 weeks, 6 months, and 12 months were 160, 220, and 250 mL, respectively. Annualized rates of severe exacerbations (RR, 0.41), proportion of patients receiving OCS (RR, 0.59), and number of unscheduled physician visits (mean difference, -2.34) were significantly reduced with omalizumab at 12 months when compared with baseline.